跳至主要内容
临床试验/JPRN-UMIN000016337
JPRN-UMIN000016337已完成未知

Randomized Controlled Trial for H.pylori first line eradication therapy considering clarithromycin resistance: PCAB vs PPI - PCAB-based H.pylori first line eradication study (CAP study)

Yokohama City University Hospital0 个研究点目标入组 147 人开始时间: 2015年2月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
147

研究概览

简要总结

The ITT and PP eradication rates(ER) of V-AC in the CAM-susceptible H.pylori-infected patients were 87.3% (95%CI: 75.5-94.7%) and 88.9% (77.4-95.8%). The respective ER of PPI-AC were 76.5% (62.5-87.2%) and 86.7% (73.2-94.9%). No significant difference was observed between the groups in ITT(P = .21) or PP (P = .77) analyses. The questionnaire scores did not differ significantly between the groups. Both the ITT and PP ER of V-AC in the CAM-resistant patients were 82.9% (67.9%- 92.8%).

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Past history of taking eradication therapy. Pregnancy or lactation. Past history of allergy for the drugs used in this therapy. Severe liver dysfunction, Severe renal dysfunction, Severe heart dysfunction. Patients who are disqualified for the study by physicians.

研究者

相似试验